Acepodia partners with Pfizer Ignite to expand ACC therapies for autoimmune diseases.

Acepodia, a clinical-stage biotechnology firm, has partnered with Pfizer Ignite to enhance its Antibody-Cell Conjugation (ACC) therapies for autoimmune diseases. This collaboration will provide Acepodia with strategic support and resources, enabling it to expand its applications beyond cancer treatments.

September 03, 2024
5 Articles